| Phase 1/24 trials |
|
Phase 1/2
|
NCT07421700 |
Mar 2026 → Dec 2027 expected |
urothelial carcinoma |
Pfizer |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT07227415 |
Feb 2026 → Nov 2027 expected |
clear cell renal carcinoma |
Pfizer |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT07227298 |
Jan 2026 → Mar 2029 expected |
non-small cell lung carcinoma |
Pfizer |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT07227012 |
Dec 2025 → Oct 2027 expected |
hepatocellular carcinoma |
Pfizer |
Recruiting
|
No outcome recorded
|
| Phase 22 trials |
|
Phase 2
|
NCT07476287 |
Jul 2026 → Mar 2028 expected |
small cell lung carcinoma |
Pfizer |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07489066 |
Jun 2026 → Jul 2028 expected |
non-small cell squamous lung carcinoma |
Pfizer |
Recruiting
|
No outcome recorded
|
| Phase 2/32 trials |
|
Phase 2/3
|
NCT07392892 |
May 2026 → Jan 2032 expected |
esophageal adenocarcinoma, gastric cancer, gastroesophageal cancer |
Pfizer |
Recruiting
|
No outcome recorded
|
|
Phase 2/3
|
NCT07226999 |
Dec 2025 → Jun 2030 expected |
small cell lung carcinoma |
Pfizer |
Recruiting
|
No outcome recorded
|
| Phase 33 trials |
|
Phase 3
|
NCT07578649 |
Oct 2026 → Jun 2029 expected |
endometrial cancer |
Pfizer |
Not yet recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT07222566 |
Jan 2026 → Feb 2029 expected |
non-small cell lung carcinoma |
Pfizer |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT07222800 |
Dec 2025 → Feb 2030 expected |
colonic disorder, colorectal cancer, rectal disorder |
Pfizer |
Recruiting
|
No outcome recorded
|